LivaNova PLC
NASDAQ:LIVNMedical - Devices
+$0.76 today
- Market cap
- $5.21B
- Beta
- 0.88
- P/E (TTM)
- 40.5
- EPS (TTM)
- $1.96
Volume 1.32M
Average 0.79M
LIVN Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
LivaNova PLCNASDAQ: LIVN
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue grows in line with its trailing trend
Q3 FY2026 cost of revenue of $128.1M rose 13.5% year over year, in line with the +13.8% change in trailing-twelve-month cost of revenue. Sequentially, it rose 9.6% from the prior quarter. Over 3 fiscal years it compounded at +12.5% a year.
Context
- Cost of revenue amounted to 32.3% of revenue in FY2025, up 1.8 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +13.5% toward the trailing-twelve-month pace of +13.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 448.2M USD
- Year-over-year change
- +17.2%
- 4-year CAGR
- +8.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 448.2M | +17.2% |
| FY2024 | 2024-12-31 | 382.56M | +0.1% |
| FY2023 | 2023-12-31 | 382.3M | +21.5% |
| FY2022 | 2022-12-31 | 314.58M | -4.5% |
| FY2021 | 2021-12-31 | 329.37M | — |
Cost of Revenue vs competitors
How LIVN compares with its peers on the latest reported figures
- LIVN's LTM Sep 2026 cost of revenue of $483.49M is the 6th highest of the 10 companies compared; the peer median is $576.17M.
- Its year-over-year change of +13.8% is the 3rd highest of 10, against a peer median of +0.0%.
- Cost of revenue amounts to 32.1% of revenue for LIVN, versus a peer median of 28.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $12.51B | +0.0% | +5.9% | 33.3% | |
| LTM Jun 2026 | $6.06B | -11.0% | +7.8% | 28.8% | |
| LTM Jun 2026 | $2.2B | +5.0% | +5.6% | 38.8% | |
| LTM Jun 2026 | $1.44B | +19.7% | +4.4% | 22.0% | |
| LTM Jun 2026 | $576.17M | -0.9% | +2.7% | 42.6% | |
| LTM Sep 2026 | $483.49M | +13.8% | +12.5% | 32.1% | |
| LTM Jun 2026 | $124.64M | -6.8% | +26.3% | 13.9% | |
| LTM Mar 2026 | $78.91M | +141.8% | +70.6% | 52.0% | |
| LTM Mar 2026 | $21.6M | +1.8% | +20.5% | 21.7% | |
| LTM Mar 2026 | $8.55M | -0.9% | +18.5% | 14.5% | |
MOBIMobia Medical, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LIVN) | $576.17M | +0.0% | +7.8% | 28.8% | |
Competitors are the stored peer set for LIVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.04B | 1.02B | 1.15B | 1.25B | 1.39B |
| Cost of Revenue | 329.37M | 314.58M | 382.3M | 382.56M | 448.2M |
| Gross Profit | 705.99M | 707.23M | 771.25M | 870.87M | 939.9M |
| Gross Margin | 68.2% | 69.2% | 66.9% | 69.5% | 67.7% |
| Research & Development | 183.41M | 155.81M | 193.82M | 182.51M | 185.8M |
| Selling, General & Admin | 471.9M | 469.24M | 518.13M | 526.27M | 548.8M |
| Operating Expenses | 706.78M | 783.98M | 839.75M | 741.82M | 740.5M |
| Depreciation & Amortization | 67.99M | 57.8M | 60.86M | 51.14M | 42M |
| EBITDA | (6.33M) | 30.9M | 38.48M | 202.52M | (129.5M) |
| EBITDA Margin | -0.6% | 3.0% | 3.3% | 16.2% | -9.3% |
| Operating Income | (784K) | (76.75M) | (68.5M) | 129.05M | 199.4M |
| Operating Margin | -0.1% | -7.5% | -5.9% | 10.3% | 14.4% |
| Interest Income | 435K | 4.7M | 22.01M | 30.08M | 18.98M |
| Interest Expense | 50.15M | 48.25M | 58.85M | 63.07M | 49.29M |
| Other Income / Expenses | (123.84M) | 1.56M | (12.83M) | (40.74M) | (420.2M) |
| Income Before Tax | (124.62M) | (75.2M) | (81.33M) | 88.31M | (220.8M) |
| Pre-Tax Margin | -12.0% | -7.4% | -7.1% | 7.0% | -15.9% |
| Income Tax Expense | 11.2M | 11.05M | (98.88M) | 25.06M | 21.6M |
| Net Income | (135.82M) | (86.25M) | 17.55M | 63.23M | (242.5M) |
| Net Margin | -13.1% | -8.4% | 1.5% | 5.0% | -17.5% |
| EPS (Basic) | (2.68) | (1.61) | 0.33 | 1.17 | (4.45) |
| EPS (Diluted) | (2.68) | (1.61) | 0.32 | 1.16 | (4.45) |
| Weighted Avg Shares | 50.63M | 53.5M | 53.9M | 54.24M | 54.5M |
| Weighted Avg Shares (Diluted) | 50.63M | 53.5M | 54.21M | 54.57M | 54.5M |
LivaNova PLC
NASDAQ:LIVN
Intrinsic Alpha fair value
Locked
Current Price
$94.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.